{
  "id": 9027772,
  "title": "Novo Nordisk Shares Sink Nearly 8% After Wegovy Maker’s 2030 Plan Disappoints",
  "url": "https://urgent.news/2026/09/21/novo-nordisk-shares-sink-nearly-8-after-wegovy-makers-2030-plan",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-21T22:02:46.000Z",
  "source": {
    "name": "The Rio Times",
    "slug": "the-rio-times",
    "url": "https://www.riotimesonline.com/novo-nordisk-shares-sink-2030-plan-2026/"
  },
  "original_language": "en",
  "account": "Novo Nordisk's shares plummeted nearly 8% following the company's disappointing 2030 plan announcement. The Danish drugmaker, known for its popular diabetes and weight loss medications Ozempic and Wegovy, unveiled its plans for new drugs during a Capital Markets Day in London. Investors were hoping for a more ambitious growth story, but instead, Novo Nordisk only projected average growth for the next five years. CEO Maziar Mike Doustdar stated that the company aims for more than five \"multi-blockbuster\" drugs by 2030, with a projected pipeline revenue of over 150 billion Danish kroner (approximately US$23.1 billion) by 2035. Novo Nordisk also intends to serve ten times more patients with obesity on GLP-1 pills and aims to reach more than 60 million patients worldwide by 2030. The company's operating margin and dividend per share are expected to remain stable. However, the market did not respond positively to these projections, as investors were seeking a more aggressive growth strategy. The expiration of Novo Nordisk's US patent protection on semaglutide, the active ingredient in Ozempic and Wegovy, in 2032 is seen as a significant challenge for the company, as generics and competitors enter the market.",
  "summary": "Novo Nordisk shares fell 7.7% in Copenhagen after the Wegovy maker promised only peer-level growth to 2030 at its London investor day. The post Novo Nordisk Shares Sink Nearly 8% After Wegovy Maker’s 2030 Plan Disappoints appeared first on The Rio Times .",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}